NASDAQ · Financial Statements
enGene Therapeutics Inc. (ENGN) Financial Statements
$1.73
NASDAQ: ENGN
Market Cap $115.89M
Overview Financials Dividend enGene Therapeutics Inc. most recently reported annual revenue of $0, net profit of $-117.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-16.0M $-19.0M $-26.0M $-62.0M $-123.0M Net Profit $-23.0M $-24.0M $-100.0M $-55.0M $-117.0M EPS $-0.01 $-1.84 $-4.24 $-1.46 $-2.29 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $131.0M $132.0M $87.0M $311.0M $221.0M Total Liabilities $4.0M $5.0M $14.0M $39.0M $54.0M Cash $1.0M $0 $82.0M $173.0M $50.0M Borrowings $4.0M $32.0M $10.0M $25.0M $32.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-16.0M $-18.0M $-25.0M $-48.0M $-99.0M Investing Cash Flow $0 $0 $-1.0M $-127.0M $-27.0M Financing Cash Flow $0 $0 $-4.0M $-7.0M $0 Net Cash Flow $6.0M $9.0M $61.0M $91.0M $-123.0M Free Cash Flow $-16.0M $-18.0M $-25.0M $-49.0M $-101.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.07 EV / EBITDA -0.93 FCF Yield -80.02% Quick Ratio 10.21 Interest Coverage -1.53 Return 1Y -46.58% Return 3Y -82.57% Return 5Y —
Screens featuring this stock